506 related articles for article (PubMed ID: 18495905)
1. Pharmacoeconomic concepts in antiplatelet therapy: understanding cost-effectiveness analyses using clopidogrel as an example.
Weintraub WS
J Cardiovasc Pharmacol Ther; 2008 Jun; 13(2):107-19. PubMed ID: 18495905
[TBL] [Abstract][Full Text] [Related]
2. Pharmacoeconomics.
Sule NS; Nerurkar RP; Kamath SA
J Assoc Physicians India; 2002 Aug; 50():1057-62. PubMed ID: 12421032
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long-term model based on the CURE trial.
Lindgren P; Jönsson B; Yusuf S
J Intern Med; 2004 May; 255(5):562-70. PubMed ID: 15078498
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of drug-eluting stents including the economic impact of late stent thrombosis.
Filion KB; Roy AM; Baboushkin T; Rinfret S; Eisenberg MJ
Am J Cardiol; 2009 Feb; 103(3):338-44. PubMed ID: 19166686
[TBL] [Abstract][Full Text] [Related]
5. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
Führlinger S
Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
[TBL] [Abstract][Full Text] [Related]
6. Guidelines for performing a pharmacoeconomic analysis.
Jolicoeur LM; Jones-Grizzle AJ; Boyer JG
Am J Hosp Pharm; 1992 Jul; 49(7):1741-7. PubMed ID: 1621734
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of clopidogrel: seeing through the smoke.
Goldman L; Gaspoz JM
Med Decis Making; 2008; 28(6):803-9. PubMed ID: 18556636
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacoeconomic evaluation of clopidogrel in acute coronary syndromes. Long-term treatment, secondary prophylaxis, and percutaneous coronary intervention].
Bramkamp M; Szucs TD
Herz; 2008 Feb; 33(1):60-70. PubMed ID: 18273579
[TBL] [Abstract][Full Text] [Related]
9. Pharmacoeconomics.
Ahuja J; Gupta M; Gupta AK; Kohli K
Natl Med J India; 2004; 17(2):80-3. PubMed ID: 15141600
[TBL] [Abstract][Full Text] [Related]
10. The pharmacoeconomics of acne treatment: where are we heading?
Inglese MJ; Fleischer AB; Feldman SR; Balkrishnan R
J Dermatolog Treat; 2008; 19(1):27-37. PubMed ID: 18273722
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of ticagrelor in acute coronary syndromes.
Henriksson M; Janzon M
Expert Rev Pharmacoecon Outcomes Res; 2013 Feb; 13(1):9-18. PubMed ID: 23402441
[TBL] [Abstract][Full Text] [Related]
12. The use of decision analysis in the pharmacoeconomic evaluation of an antidepressant: a cost-effectiveness study of nefazodone.
Anton SF; Revicki DA
Psychopharmacol Bull; 1995; 31(2):249-58. PubMed ID: 7491376
[TBL] [Abstract][Full Text] [Related]
13. [Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement].
Hoomans T; van der Roer N; Severens JL; Delwel GO
Ned Tijdschr Geneeskd; 2010; 154():A958. PubMed ID: 20699045
[TBL] [Abstract][Full Text] [Related]
14. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
Motovska Z; Kala P
Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation for ophthalmologists.
Kuper H; Jofre-Bonet M; Gilbert C
Ophthalmic Epidemiol; 2006 Dec; 13(6):393-401. PubMed ID: 17169853
[TBL] [Abstract][Full Text] [Related]
16. Potential unrecognised costs of clopidogrel pretreatment in acute coronary syndrome.
Bae JP; Dobesh PP; McCollam PL; Khoynezhad A
J Med Econ; 2009; 12(4):325-30. PubMed ID: 19824808
[TBL] [Abstract][Full Text] [Related]
17. Economic outcomes and contemporary pharmacy practice.
Reeder CE
Am Pharm; 1993 Dec; NS33(12 Suppl):S3-6. PubMed ID: 8109541
[TBL] [Abstract][Full Text] [Related]
18. Current antiplatelet therapies: benefits and limitations.
Angiolillo DJ; Guzman LA; Bass TA
Am Heart J; 2008 Aug; 156(2 Suppl):S3-9. PubMed ID: 18657680
[TBL] [Abstract][Full Text] [Related]
19. [Health outcomes analysis and its applications].
Carrera-Hueso FJ
Rev Med Univ Navarra; 1997; 41(4):237-44. PubMed ID: 10420964
[TBL] [Abstract][Full Text] [Related]
20. Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial.
Sculpher MJ; Lozano-Ortega G; Sambrook J; Palmer S; Ormanidhi O; Bakhai A; Flather M; Steg PG; Mehta SR; Weintraub W
Am Heart J; 2009 May; 157(5):845-52. PubMed ID: 19376310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
